We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Momenta Betting Biosimilar Push Will Put Balance Sheet Back in the Black
Momenta Betting Biosimilar Push Will Put Balance Sheet Back in the Black
February 15, 2013
Momenta Pharmaceuticals will rely on milestone payments from three follow-on biologic projects with Baxter to return the company to profitability. Ongoing patent litigation, withering revenue streams and biosimilar development costs contributed to a net loss of $58.6 million in 2012.